Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban plus Ticagrelor vs Clopidogrel in AF and ACS
NCT04023630Phase 4Unknown
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Oct 2019
- Primary completion
- Sep 2020
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, open-label trial of ticagrelor in Atrial fibrillation (AFib) and acute coronary syndrome (ACS) (2 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: The composite endpoints of death and ischemic events at 1 year. Status: unknown.
02
Drugs
ticagrelor
03
Conditions
Atrial fibrillation (AFib)acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT04023630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04023630.